Kuros Biosciences Ltd. operates as biopharmaceutical company, which engages in developing products for tissue repair and bone regeneration. The company is headquartered in Schlieren, Zuerich and currently employs 122 full-time employees. The company went IPO on 2002-10-29. Immunodrugs are therapeutic vaccines intended for treating and preventing common chronic diseases, such as hypertension, nicotine addiction, allergic diseases, asthma, malignant melanoma and Alzheimer's disease. They are designed to instruct the patient's immune system to produce desired therapeutic antibody or T cell responses that modulate chronic disease processes. The firm has built a pipeline of different Immunodrug candidates, of which five are in clinical development. Its Immunodrug candidates are developed both in-house and together with Novartis, Pfizer and Pfizer Animal Health, among others. The firm has two subsidiaries: a wholly-owned Proteome Therapeutics GmbH and minority owned BioSupport AG.
Follow-Up Questions
Who is the CEO of Kuros Biosciences AG?
Mr. Chris Fair is the Chief Executive Officer of Kuros Biosciences AG, joining the firm since 2021.
What is the price performance of CSBTF stock?
The current price of CSBTF is $29.8, it has decreased 0% in the last trading day.
What are the primary business themes or industries for Kuros Biosciences AG?
Kuros Biosciences AG belongs to Biotechnology industry and the sector is Health Care
What is Kuros Biosciences AG market cap?
Kuros Biosciences AG's current market cap is $1.1B
Is Kuros Biosciences AG a buy, sell, or hold?
According to wall street analysts, 5 analysts have made analyst ratings for Kuros Biosciences AG, including 3 strong buy, 4 buy, 1 hold, 0 sell, and 3 strong sell
